BLASUBCUTANEOUSSOLUTIONPriority Review
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
TAKHZYRO (lanadelumab-flyo) by Dyax Corp. is kallikrein inhibitors [moa]. First approved in 2018.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAKHZYRO (lanadelumab-flyo) is a monoclonal antibody that inhibits plasma kallikrein, a key enzyme in the contact system cascade. It is approved for the treatment of hereditary angioedema (HAE) in patients 12 years of age and older. The drug works by blocking bradykinin generation, thereby preventing acute angioedema attacks.
$6.0MPart D
PeakThe product is in peak commercial stage with stable but modest Part D spending, suggesting a mature, niche indication with limited commercial expansion opportunities.
Mechanism of Action
Kallikrein Inhibitors
Pharmacologic Class:
Plasma Kallikrein Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea
Started Sep 2026
35 enrolled
Hereditary Angioedema (HAE)
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
Career Relevance
TAKHZYRO offers limited near-term career growth given its peak lifecycle stage and modest commercial footprint; roles focus on maintaining market position in a niche HAE indication rather than scaling operations. Career progression on this brand is best suited for professionals seeking stability in a specialized market with deep clinical expertise valued.
Worked on TAKHZYRO at Dyax Corp.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.